Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA240-0029  |   NCT07063745

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 2/Phase 3
  • Ícono de género masculino y femenino
  • 18+
  • 84
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
    1. Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
      1. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
        1. Participants must have at least 1 measurable lesion as per RECIST v1.1.

          Criterios de exclusión

          Criterios de exclusión Icon
          • Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
            1. Participants must not have symptomatic brain metastases or spinal cord compression.
              1. Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
                1. Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
                  Información Adicional *
                  • Other protocol-defined Inclusion/Exclusion criteria apply.

                    Opciones de tratamiento

                    Brazos del estudio

                    INTERVENCIÓN ASIGNADA

                    Brazos del estudio

                    Active Comparator: Arm A: BMS-986504 + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Brazos del estudio

                    Active Comparator: Arm B: BMS-986504 + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Brazos del estudio

                    Placebo Comparator: Arm C: Placebo + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo

                    Brazos del estudio

                    Placebo Comparator: Arm D: Placebo + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo

                    Brazos del estudio

                    Active Comparator: Arm E: BMS-986504 + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Brazos del estudio

                    Placebo Comparator: Arm F: Placebo + Pembrolizumab + Chemotherapy

                    INTERVENCIÓN ASIGNADA
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo
                    Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                    Verifique su elegibilidad
                    Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                    Compatibilizar con un estudio
                    Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                    Seleccione una ubicación del centro del estudio
                    Seleccione una ubicación del centro del estudio que sea conveniente para usted
                    Registrarse
                    Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                    Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias